Effectiveness of indapamide/amlodipine single-pill combination in patients with isolated systolic hypertension: post-hoc analysis of the ARBALET study

• Published in: BMC cardiovascular disorders Vol. 22; no. 1; p. 85
• Main Authors: Kobalava, Zh D, Kolesnik, Eteri L, Shavarova, E K, Goreva, L A, Karapetyan, L V
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.03.2022; BioMed Central; BMC
• Subjects: Aged; Amlodipine; Amlodipine - adverse effects; Antihypertensive Agents - adverse effects; Blood Pressure; Care and treatment; Combination therapy; Diagnosis; Dosage and administration; Drug Combinations; Drug therapy, Combination; Female; Humans; Hypertension; Hypertension - diagnosis; Hypertension - drug therapy; Indapamide; Indapamide - adverse effects; Indapamide/amlodipine single-pill combination; Isolated systolic hypertension; Male; Middle Aged; Original Research; Patient outcomes; Perindopril - therapeutic use; Risk factors; Treatment Outcome; Russia; Combination therapy; Indapamide/amlodipine single-pill combination; Isolated systolic hypertension
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-022-02514-y

This study evaluated the effectiveness of treatment with an indapamide/amlodipine single-pill combination (SPC) in outpatients with uncontrolled isolated systolic hypertension (ISH) aged over 55 years in real-life clinical practice. This was a post-hoc analysis of the subgroup of patients with ISH from ARBALET, a 3-month, multicenter, observational, open-label study conducted in Russia among patients with grade I or II hypertension who were either uncontrolled on previous antihypertensive treatment or treatment-naïve. The effectiveness of indapamide/amlodipine SPC was assessed by the change in office systolic blood pressure (SBP) and the rate of target SBP (< 140 mmHg) achievement at 2 weeks, 1 month and 3 months, in four age groups: 55-59 years, 60-69 years, 70-79 years, and 80 years or older. The ARBALET study recruited 2217 patients, of whom 626 had ISH and were included in this post-hoc analysis (mean age 66.1 ± 7.8 years; 165 men [26.4%] and 461 women [73.6%]). Target SBP < 140 mmHg was achieved in 43%, 75% and 93% of patients at 2 weeks, 1 and 3 months, respectively. SBP decreased from baseline by 18.8 ± 10.5 mmHg, 27.2 ± 10.6 mmHg and 31.8 ± 9.9 mmHg at 2 weeks, 1 month and 3 months, respectively. In the groups of patients aged 55-59, 60-69, 70-79, and ≥ 80 years, SBP reductions at 3 months compared with baseline were - 30.3 ± 9.4, - 32.4 ± 9.7, - 32.5 ± 10.7, and - 28.9 ± 9.6 mmHg, respectively. This post-hoc analysis of the observational ARBALET study showed that indapamide/amlodipine SPC was associated with significant reductions in BP and high rates of target BP achievement in a broad age range of patients with ISH treated in routine clinical practice. ISRCTN40812831.